Life science news and medical media coverage for healthcare professionals
Breast cancer home injections: Convenient for patients, complex for insurers
Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.
Chemo hair loss: Why some patients feel it more deeply
Distress from chemotherapy-induced hair loss is disproportionately higher among younger women and Black women, highlighting an unmet need for targeted support.
Salivary gland cancer: Is HER2-low the new HER2-positive?
Trastuzumab rezetecan demonstrated antitumor activity in advanced salivary gland carcinoma, particularly in HER2-high disease, with a 50% objective response rate.
Brain metastases: Why less radiation, more often, improves outcomes
Multicancer tests: Can we screen without knowing the outcome?
Lung cancer in never smokers: The 60x risk factor you might be missing
Multicancer early detection: Can we screen for what we can't treat?
Why are we still treating cancer prevention as adjunctive care?
Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Liver disease: Is coffee a daily dose of prevention?
Regular coffee consumption is associated with a reduced risk of liver disease, with a specific daily intake range appearing most beneficial. The protective effect extends across various liver conditions, including fibrosis and cirrhosis.
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Seladelpar and elafibranor offer new therapeutic avenues for primary biliary cholangitis patients with inadequate response to ursodeoxycholic acid.
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
A 24-week anti-PD-1 antibody regimen reduced HBsAg and enhanced HBV-specific T cell responses in patients with chronic hepatitis B, offering a potential functional cure strategy.
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
Why primary sclerosing cholangitis remains a therapeutic graveyard
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
ACLF: Why G-CSF works for some, but fails others
MASH: Why diabetes management now demands a liver-first approach?
Seladelpar and elafibranor: second-line options for PBC
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Xylitol, a common sugar alcohol, has been linked to an elevated risk for major adverse cardiovascular events, raising concerns about its widespread use.
Peripheral arterial disease: Why early detection still eludes us
Peripheral arterial disease often goes undiagnosed until advanced stages, leading to preventable complications. Early detection is critical for improving patient outcomes.
Hypertension: Do shorter wall squats work as well for older women?
Isometric wall squats reduced blood pressure in older women with hypertension, but a higher dose did not offer superior postexercise hypotension.
Endocarditis: Why fixed-dose ampicillin often misses the mark
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Evolocumab: Is LDL-C reduction finally translating to lives saved?
Tactical athletes need more than a sports physical
GLP-1s: Is eligibility missing half your high-risk patients?
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Type 1 diabetes incidence in Norwegian children rose 11% after rotavirus vaccination began, but similar rises followed unrelated vaccine changes.
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
Eloralintide combined with tirzepatide cut body weight by up to 23.3% at 48 weeks in adults with obesity and type 2 diabetes, phase 2b data show.
CBL-514: Is visceral fat reduction the real story?
CBL-514 reduced visceral fat volume by 10.45% versus a 11.76% rise on placebo in a 40-person MRI subgroup, but the weight regain claim rests on rat data.
Bariatric surgery: The hidden hernia risk you're missing
Survodutide: Is 9.8% weight loss enough for its GI cost?
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
Marathon running with type 1 diabetes: Is it finally safe?
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
Type 1 diabetes screening: Why one protocol worked across 8 nations
Epilepsy: Is art the missing piece in holistic patient care?
A new exhibit showcases artists living with epilepsy, aiming to reframe public perception of the condition beyond its clinical manifestations.
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
The FDA approved Juvmo for adults with Parkinson's disease, targeting cognitive decline, a common and debilitating aspect of the condition.
Routine childhood vaccines: Less coverage means more than just infections
Routine childhood vaccination coverage has stagnated globally, with persistent inequities amplified by the COVID-19 pandemic, raising concerns for future health outcomes.
Spike sorting: Is your 'black box' holding back neural insights?
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
Can mice learn to control their own brains? A new neurofeedback system
Fibromyalgia: Is the pain real if the tissue damage isn't?
Lifelong odor sensitivity: What early exposure means for your patients?
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full story
Idiopathic Pulmonary Fibrosis
Clostridioides difficile
• Oct 21 – 23ESMO 2026 • Madrid, ES 
• Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12LIVEJoint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
AdvertisementAdvertisementAdvertisement
Advertisement
TorontoOct 21 – 23 2026Get on-site reporting the moment it publishes.
TorontoAttending Joint ACTRIMS-ECTRIMS 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
